Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism.
暂无分享,去创建一个
Rui M. M. Branca | Y. Pawitan | P. Validire | V. Lazar | J. Soria | J. J. van den Oord | R. Lewensohn | L. Kanter | J. Lehtiö | M. Pernemalm | P. Girard | J. Forshed | S. Påhlman | L. de Petris | R. Branca
[1] A. Harris,et al. How cancer metabolism is tuned for proliferation and vulnerable to disruption , 2012, Nature.
[2] Yoo Jin Jung,et al. The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.
[3] M. Okada,et al. Cathepsin D as a potential prognostic marker for lung adenocarcinoma. , 2012, Pathology, research and practice.
[4] Li Ding,et al. Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.
[5] K. Cibulskis,et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.
[6] Angela N. Brooks,et al. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.
[7] Nadav S. Bar,et al. Landscape of transcription in human cells , 2012, Nature.
[8] Chih-Chiang Tsou,et al. Label-free Quantitative Proteomics and N-Glycoproteomics Analysis of KRAS-activated Human Bronchial Epithelial Cells* , 2012, Molecular & Cellular Proteomics.
[9] P. Massion,et al. In-depth Proteomic Analysis of Nonsmall Cell Lung Cancer to Discover Molecular Targets and Candidate Biomarkers* , 2012, Molecular & Cellular Proteomics.
[10] V. Shoshan-Barmatz,et al. Expression of a truncated active form of VDAC1 in lung cancer associates with hypoxic cell survival and correlates with progression to chemotherapy resistance. , 2012, Cancer research.
[11] Vito Pistoia,et al. Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy , 2012, Science Translational Medicine.
[12] M. Seckl,et al. HIF-2α expression is suppressed in SCLC cells, which survive in moderate and severe hypoxia when HIF-1α is repressed. , 2012, The American journal of pathology.
[13] Brian Keith,et al. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.
[14] R. Memmott,et al. Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis , 2010, Cancer Prevention Research.
[15] W. Hsu,et al. Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer , 2009, Thorax.
[16] J. Buhmann,et al. Protein Identification False Discovery Rates for Very Large Proteomics Data Sets Generated by Tandem Mass Spectrometry* , 2009, Molecular & Cellular Proteomics.
[17] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[18] E. Åvall-Lundqvist,et al. Ovarian carcinoma cells with low levels of β-F1-ATPase are sensitive to combined platinum and 2-deoxy-d-glucose treatment , 2009, Molecular Cancer Therapeutics.
[19] William Stafford Noble,et al. Improvements to the percolator algorithm for Peptide identification from shotgun proteomics data sets. , 2009, Journal of proteome research.
[20] Lukas M Orre,et al. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. , 2009, Lung cancer.
[21] Anthony Mancuso,et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.
[22] H. Kalbacher,et al. Cathepsin D: a cellular roadmap. , 2008, Biochemical and biophysical research communications.
[23] N. Denko,et al. Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.
[24] B. Persson,et al. Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms , 2008, Proteomics.
[25] V. Shoshan-Barmatz,et al. Uncovering the role of VDAC in the regulation of cell life and death , 2008, Journal of bioenergetics and biomembranes.
[26] William Stafford Noble,et al. Semi-supervised learning for peptide identification from shotgun proteomics datasets , 2007, Nature Methods.
[27] F. López-Ríos,et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. , 2007, Cancer research.
[28] J. Crowley,et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[29] V. Vetvicka,et al. Procathepsin D expression correlates with invasive and metastatic phenotype of MDA-MB-231 derived cell lines. , 2007, International journal of biological macromolecules.
[30] M. Dewhirst,et al. Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer , 2005 .
[31] C. Jun,et al. Performance of some variable selection methods when multicollinearity is present , 2005 .
[32] K. Greulich,et al. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. , 2004, Genomics.
[33] Erik Johansson,et al. Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm) , 2004, Analytical and bioanalytical chemistry.
[34] David E. Misek,et al. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. , 2004, Carcinogenesis.
[35] V. Shoshan-Barmatz,et al. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. , 2004, The Biochemical journal.
[36] G. Semenza,et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.
[37] John C Reed,et al. The bioenergetic signature of cancer: a marker of tumor progression. , 2002, Cancer research.
[38] A. Harris,et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival , 2001, British Journal of Cancer.
[39] Alfonso Valencia,et al. A hierarchical unsupervised growing neural network for clustering gene expression patterns , 2001, Bioinform..
[40] Bonnie F. Sloane,et al. Unraveling the role of proteases in cancer. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[41] G. Semenza,et al. Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.
[42] M. Schwartz. Tissue cathepsins as tumor markers. , 1995, Clinica chimica acta; international journal of clinical chemistry.
[43] H. Rochefort,et al. Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. , 1989, Molecular endocrinology.
[44] V. Shoshan-Barmatz,et al. VDAC, a multi-functional mitochondrial protein as a pharmacological target. , 2012, Mitochondrion.
[45] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.